BOK displays cell death-independent tumor suppressor activity in non-small cell lung carcinoma. by Moravcikova, Erika et al.
BOK displays cell death-independent tumor suppressor activity in non-small 
cell lung carcinoma 
Erika Moravcikova
1,2
, Evzen Krepela
3
, Vera S Donnenberg
2
, Albert D Donnenberg
4
, Kamila 
Benkova
5
, Tatiana Rabachini
1
, Yuniel Fernandez-Marrero
1
, Daniel Bachmann
1
, Thomas 
Kaufmann
1
   
1
Institute of Pharmacology, Faculty of Medicine, University of Bern, Switzerland 
2
Current address: Department of Cardiothoracic Surgery, School of Medicine, University of 
Pittsburgh, Pennsylvania, USA 
3
Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles 
University, Prague, Czech Republic 
4
Department of Medicine, School of Medicine, University of Pittsburgh, Pennsylvania, USA 
5
Department of Pathology, Hospital Bulovka, Prague, Czech Republic  
Correspondence to:  
Prof. Dr. Thomas Kaufmann 
Institute of Pharmacology 
Inselspital, INO-F 
3010 BERN 
Switzerland 
Phone: +41 31 632 32 89 
Fax: +41 31 632 49 92 
E-mail: thomas.kaufmann@pki.unibe.ch  
Running title: Bcl-2 family member BOK in non-small cell lung carcinoma 
 
Keywords: Non-small cell lung carcinoma, BOK, apoptosis, epithelial-to-mesenchymal 
transition, Bcl-2 family 
 Abbreviations: 4-OHT: 4-hydroxytamoxifen, BOK: BCL-2 ovarian killer, EMT: epithelial-to-
mesenchymal transition, LAC: lung adenocarcinoma, LCLC: large cell lung carcinoma, NSCLC: 
non-small cell lung carcinoma, SLC: sarcomatoid lung carcinoma, SQCLC: squamous cell lung 
carcinoma, UNDIF: undifferentiated lung carcinoma,   
Article category: Research article: 2.1.2 Cancer Genetics and Epigenetics, 2.1.4 Molecular 
Cancer Biology  
Novelty and Impact 
BOK is one of the most frequently deleted BCL-2 family members in human cancer. Here we 
show a possible cell death-independent tumor suppressor function of BOK in NSCLC. We found 
that, in vitro, BOK is epigenetically silenced and that its overexpression decreases anchorage-
independent growth, TGF-beta induced migration and epithelial-to-mesenchymal transition. In 
vivo, BOK levels are predictive of survival in lymph node positive patients. BOK expression 
might therefore serve as prognostic marker in later stage NSCLC. 
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Abstract 
Since the genomic region containing the Bcl-2-related ovarian killer (BOK) locus is frequently 
deleted in certain human cancers, BOK is hypothesized to have a tumor suppressor function. In 
the present study, we analyzed primary non-small cell lung carcinoma (NSCLC) tumors and 
matched lung tissues from 102 surgically treated patients. We show that BOK protein levels are 
significantly downregulated in NSCLC tumors as compared to lung tissues (P<0.001). In 
particular, we found BOK downregulation in NSCLC tumors of grades two (P=0.004, n=35) and 
three (P=0.031, n=39) as well as in tumors with metastases to hilar (pN1) (P=0.047, n=31) and 
mediastinal/subcarinal lymph nodes (pN2) (P=0.021, n=18) as opposed to grade one tumors 
(P=0.688, n=7) and tumors without lymph node metastases (P=0.112, n=51). Importantly, in 
lymph node positive patients, BOK expression greater than the median value was associated with 
longer survival (P=0.002, Mantel test). Using in vitro approaches, we provide evidence that 
BOK overexpression is inefficient in inducing apoptosis but that it inhibits TGFβ-induced 
migration and epithelial-to-mesenchymal transition (EMT) in lung adenocarcinoma-derived 
A549 cells. We have identified epigenetic mechanisms, in particular BOK promoter methylation, 
as an important means to silence BOK expression in NSCLC cells. Taken together, our data 
point toward a novel mechanism by which BOK acts as a tumor suppressor in NSCLC by 
inhibiting EMT. Consequently, the restoration of BOK levels in low-BOK-expressing tumors 
might favor the overall survival of NSCLC patients. 
 
Introduction 
Bcl-2-related ovarian killer (BOK) is a poorly understood member of the Bcl-2 protein family. It 
is similar in domain structure and homologous in amino acid sequence to the pro-apoptotic 
family members BAX and BAK. Accordingly, BOK was shown to have proapoptotic function 
upon overexpression (1-4). Even though it is known that overexpressed BOK leads to the release 
of cytochrome-c from mitochondria leading to procaspase-9 activation, exact mechanisms of this 
pro-death function are controversially discussed as is its pro-apoptotic function under 
physiological conditions (1, 2, 5-10). Intriguingly, most of the cytoplasmic BOK seems to be 
localized at the endoplasmic reticulum (2, 11, 12), by a mechanism requiring its C-terminal tail-
anchor (2), where it strongly interacts with IP3 receptors and is subject to posttranslational 
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regulation through ubiquitination and proteasomal degradation (1, 13, 14). Significant amounts 
of BOK are also found within the nuclear compartment (2, 11) and non-apoptotic roles in 
regulation of proliferation (12), and even protective roles in response to specific stressors or in 
specialized cell types have been proposed (2, 15). 
Recently, it was shown that – unexpectedly - the BOK gene is relatively frequently deleted in 
human cancers (16). BOK might therefore have a previously unrecognized tumor suppressor 
function. 
Lung cancers, 80% of which are NSCLC type tumors, remain the leading cause of cancer-related 
deaths worldwide (17). Importantly, NSCLCs are well-known to develop high resistance towards 
chemo- and radiotherapy and patients often relapse because of progression of the primary tumor 
to metastatic disease. In this study, we investigated the tumor suppressor potential of BOK and 
its possible molecular function(s) in NSCLC cells and tissues. The results of our study show that 
high levels of BOK in primary NSCLC tumors correlate with longer overall survival of NSCLC 
patients and that BOK plays a role in the epithelial-to-mesenchymal transition and migration of 
NSCLC cells whereas it might only play a minor role in apoptosis induction. 
 
Materials and Methods 
Reagents 
High glucose Dulbecco’s Modified Eagle Medium (DMEM with GlutaMAX), trypsin-EDTA 
solution and penicillin/streptomycin stock solutions were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA). Fetal calf serum (FCS, Sera Pro, ultra-low endotoxin) was 
purchased from Pan Biotech (Aidenbach, DE). RPMI 1640 AQmedia
TM
 and 4-hydroxytamoxifen 
(4-OHT) were from Sigma Aldrich Chemie GmBH (Buchs, Switzerland). 
 
NSCLC patients 
Specimens of NSCLC tumors and matched non-transformed lung parenchyma were obtained 
from 102 patients who did not received radiotherapy nor chemotherapy before surgery for lung 
cancer. Patients are characterized in supplemental data S1. The study was approved by the local 
institutional ethical committee and was conducted in accordance with the Declaration of 
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Helsinki. Signed written informed consent was obtained from each patient before entry to the  
study. Tissue samples (~1 g, wet mass) from non-necrotic parts of the tumor and from the lung at  
a site located as distantly as possible from the tumor, were excised from the resected lung lobe or  
lung immediately after surgery. All tissues were snap-frozen in liquid nitrogen and stored at -80  
˚C until protein and RNA extraction. The histopathological classification of the tumors was done  
according to the World Health Organization criteria (18) and tumor staging was performed  
according to the international pTNM system (19).  
  
NSCLC cell lines  
NSCLC cell lines used in the present study were derived from squamous cell lung carcinoma:  
CALU-1, NCI-H520, SKMES-1, lung adenocarcinoma: A549, SKLU-1, LXF-289, COLO-699,  
and large cell lung carcinoma: NCI-H1299, LCLC-103H, CORL23. CALU-1, SKMES-1, A549  
and SKLU-1 cells were obtained from the European Collection of Cell Cultures (Salisbury, UK),  
LXF-289 and COLO-699 cells were obtained from The German Collection of Microorganisms  
and Cell Cultures (Braunschweig, Germany), and NCI-H520 and NCI-H1299 cells were  
obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cell  
lines were cultured in humidified atmosphere of 5% CO2 and air at 37 ºC in DMEM or RPMI  
containing 10% heat-inactivated FCS, 10
5
 IU/l penicillin-G and 100 mg/l streptomycin.  
  
Quantitative Real time RT-PCR analysis  
Total RNA isolation, reverse transcription and PCR amplification was performed as described  
earlier (20). The BOK (GeneBank accession no. NM_032515) mRNA-directed primers were:  
forward 5'-CAGTCTGAGCCTGTGGTGAC-3', reverse 5'-TGATGCCTGCAGAGAAGATG-3'.  
β-Actin was used as reference gene (GeneBank accession no. NM_001101) using the primers:  
forward: 5'-CTGGCACCCAGCACAATG-3', reverse: 5'-GGGCCGGACTCGTCATAC-3'. Cell  
cycle regulatory gene expression was assessed using the Human Cell Cycle Primer Library  
(Biomol GmbH, Hamburg, DE).  
  
Protein extraction and immunoblotting  
Protein lysates from NSCLC cell lines were prepared in RIPA buffer (50 mM Tris-HCl pH 8.0,  
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150 mM NaCl, 1% Triton-X100, 0.5% Na-deoxycholate, 0.1% SDS, 1 mM EDTA) 
supplemented with a protease inhibitor cocktail (Complete, Roche, Basel, Switzerland), 1 µg/ml 
pepstatin, 2 mM Na3VO4 and 50 mM NaF. Total protein was determined by BCA Assay 
(Thermo Fisher Scientific, Waltham, MA, USA). Protein extracts from frozen tissue samples 
were prepared as described previously (21). Protein extracts were boiled for 5 min in reducing 
(100 mM DTT) Laemmli buffer. 50 µg per lane were separated on denaturing 7.5-20% SDS-
PAGE gradient gels and electro-transferred to PVDF membranes (0.45 µm, Merck Millipore, 
Zug, Switzerland). Membranes were probed with the following antibodies: mouse anti-Actin 
(clone C4/Actin) and mouse anti-PARP (clone C2-10) from BD Biosciences, rat anti-ATF4 
(clone W16016A, BioLegend), rabbit monoclonal anti-BOK (clone 1-5 (2)), rabbit anti-E-
cadherin (SC-7870) and mouse anti-vimentin (clone V9) from Santa Cruz Biotechnology 
(Dallas, TX, USA), mouse anti-Tubulin (clone B-5-1-2, Sigma-Aldrich) and mouse-anti-
GAPDH (clone 6C5, Merck, Millipore, Zug, Switzerland). Secondary anti-mouse and anti-rabbit 
IgG antibodies were linked to near-infrared fluorescent dyes 680CW and 800CW, respectively 
(LI-COR, Bad Homburg, Germany). Quantification was performed using Odyssey software. 
Integrated intensity values with subtracted median background were imported into SigmaStat 
(Systat Software, Point Richmond, CA, USA) for statistical analysis.  
 
Cell death analysis by flow cytometry 
Viability was determined by flow cytometry using FITC-Annexin V/ PI exclusion as previously 
described (2). Data were acquired using FACS-Calibur flow cytometer (BD Biosciences) and 
analyzed using VenturiOne software (Applied Cytometry Systems).  
 
Immunofluorescence 
A549GEV16/BOK cells were seeded on sterile glass coverslips. After attachment, 100 nM of 4-
OHT was added to induce BOK expression. The following day, cells were treated with or 
without 10 ng/ml of TGF-β2 for 48 hours. Immunofluorescence staining was performed as 
described in (2). Primary antibodies used were rabbit anti-E-cadherin (SC-7870) and mouse anti-
vimentin (clone V9) from Santa Cruz Biotechnology (Dallas, TX. USA). Secondary antibodies 
were Alexa Fluor 488- or 555-conjugated goat anti-mouse or goat anti-rabbit IgG (f(ab’)2 
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specific). Cell microphotographs were taken with Zeiss LSM 5 confocal. 
 
Boyden chamber assay 
A549GEV16/BOK and A549GEV16only cells were treated with or without 100 nM of 4-OHT 
overnight to induce/mock BOK expression, following 10 ng/ml of TGF-β2/mock treatment for 
48 h. Subsequently, 10
4
 cells were added in FCS-free medium to the upper part of the Boyden 
chamber (Transwell, Costar), while the lower part contained medium with 10% FCS. After 16-
hour incubation at 37°C and 5% CO2, inserts were washed twice in PBS, fixed in 4% 
paraformaldehyde and the non-transmigrated cells in the upper part of the 8-µm filter were 
scraped off with a cotton swab. The filter was mounted with ProLong Gold Antifade Reagent 
with DAPI (Life Technologies). Cell microphotographs were taken with Zeiss Axiovert 35 
fluorescent microscope and at least 100 DAPI-stained nuclei in the filter were counted per 
condition. 
 
Protein expression profile by flow cytometry 
A549GEV16/BOK, cells were seeded in 10-cm dishes. After attachment, cells were treated with 
or without 100 nM of 4-OHT to induce/mock BOK expression. The next day, cells were treated 
with or without 10 ng/ml of TGF-β. After 48 hours, cells were trypsinized, washed with ice cold 
PBS and counted using ViCell (Beckman Coulter). Cells were fixed with 2% paraformaldehyde 
for 20 min and blocked with goat serum for 20 min. A minimum of 7x10
4
 cells/well was added 
to a 96-well plate containing FITC, PE and APC-conjugated antibodies specific to 238 cell 
proteins (FACSCAP Lyoplate, BP80394, BD Biosciences, San Diego, CA, USA). Plates were 
incubated in dark and centrifuged at 240g for 7 min. Cells were permeabilized with 0.05% 
Saponin in immunofluorescence assay buffer (IFA, 4% calf serum, 5% human serum albumin, 2 
mM EDTA in PBS without Ca
2+
 and Mg
2+
, pH 7.2) and washed twice with IFA. Finally, DAPI 
was added to the cells at a concentration of 8 µg/ml and plates were measured the next day on 
Fortessa flow cytometer (BD Biosciences). FITC, APC and PE Calibrite beads (BD Biosciences) 
were used for compensation settings along with cells stained with DAPI alone. Acquired data 
were analyzed using VenturiOne software (Applied Cytometry Systems) and clusters were 
generated in SysStat  (San Jose, CA, USA). 
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CRSIPR/Cas9- and shRNA-mediated downregulation of BOK 
The BOK genomic locus was edited using CRISPR/Cas9 technology producing H1299, A549 
and LFX-289 cells devoid of detectable BOK protein expression. The lentiCRISPR v2 plasmid 
was a gift from Feng Zhang (Addgene plasmid #52961) (22). The following gRNA sequences 
targeting the exon 2 of human BOK was designed using the publicly available service at 
http://crispr.mit.edu: gRNA2: Fw 5’-caccgAAAGGCGTCCATGATCTCGG-3’ and Rev 5’-
aaacCCGAGATCATGGACGCCTTTc -3’; gRNA3: Fw 5’-
caccgGTCTGTGGGCGAGCGGTCAA-3’ and Rev 5’-aaacTTGACCGCTCGCCCACAGACc-3’. 
HEK 293T cells were transfected with the plasmids lentiCRISPR v2 (minus gRNA for control), 
pMD2GVSV-G, psPAX2 using X-tremeGENE HP DNA Transfection Reagent (Roche). Viruses 
were harvested after 24 h, filtered and freshly added to semi-confluent cultures of H1299 cells in 
the presence of 8 µg/mL polybrene, followed by 3 weeks of selection with 2 µg/mL puromycin. 
BOK downregulation was achieved using Mission
TM
 lentiviral plasmids (Sigma-Aldrich) 
expressing (shRNA targeting human Bok (5’-
CCGGCCGCTTCCTGAAGGCTGCCTTCTCGAGAAGGCAGCCTTCAGGAAGCGGTTTTT
G-3’) and non-targeting shRNA control (shC002). Plasmids were transiently co-transfected with 
pMD2GVSV-G and pCMVδR8.2 into HEK293T cells using X-tremeGENE HP DNA 
Transfection Reagent (Roche Diagnostics). After 48 h, viral supernatant was harvested and 
freshly used to transduce H1299 cells in the presence of 8 µg/mL polybrene, followed by 
selection with 2 µg/mL puromycin for two weeks. 
 
Chromatin immunoprecipitation (ChIP) 
1x10
7
 cells treated with decitabine for 72 h, trichostatin A for 24 h, or a combination thereof, 
were fixed in 1% formaldehyde at room temperature. Crosslinking was stopped after 10 min with 
0.125 M glycine. Cells were scraped off and washed twice with PBS. The pellet was either snap-
frozen or directly lysed in SDS lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 2 mM 
EDTA, 1% SDS containing protease and phosphatase inhibitors (Sigma, P8340, P2850, 9382)) 
and sonicated (Fisher Scientific Sonic Model 100 Dismembrator) to generate ~200 bp DNA 
fragments. Samples were centrifuged at 14’000g for 10 min and supernatant was divided for 
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inputs, acetylation studies, polymerase studies and IgG controls. Chromatin was diluted 5-fold in 
ChIP Dilution Buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 
8.1, 167 mM NaCl) and incubated with 2 µg of Histone H3K9ac antibody (61251, clone 1B10, 
Active Motif, Carlsbad, CA, USA) or 4 µg of Pol II antibody (sc-899X, Santa Cruz 
Biotechnology, Dallas, TX, USA). Samples were precipitated with Magna ChIP Protein A+G 
Magnetic beads (16-663, Millipore) at 4°C for 3 hours. Subsequently, the beads were washed 
once with low-salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-HCl, pH 8.1, 
150 mM NaCl), once with high-salt buffer (increasing NaCl to 550), once with LiCl wash buffer 
(0.25 M LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid, 1mM EDTA, 10 mM Tris, pH 8.1) 
and twice with TE Buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). Immunocomplexes were 
eluted at 65°C for 2.5 hours in 200 µl ChIP Elution Buffer (1% SDS, 0.1 M NaHCO3
-
). 
Chromatin was reverse-crosslinked with 250 µM NaCl at 65°C for 4 hours. Beads were 
centrifuged and supernatant was incubated with 0.8 U of Proteinase K (New England Biolabs, 
Inc., Ipswich, MA) at 45°C for 1 hour. DNA was purified with GeneJET PCR Purification kit 
(0702, Thermo Fisher Scientific). 3 µl of DNA were used for qPCR in Fast Start Universal Sybr 
Green Master Mix (Roche Diagnostics) on a Stratagene Mx3005 analyzer (Agilent, Santa Clara, 
CA, USA). ROX was used as a reference dye. The primers used for the amplification were: BOK 
Promoter1 Fw: 5’-TCTAGGTCCCCACTGCTCTG-3’ and Rev: 5’-
GAGACGCTTTCCGAGCTTC-3’; BOK Promoter2 Fw: 5’-TCGGGGAATGTCTGTAGCTG-
3’ and Rev: 5’-GGGTCCGCTCTCGTTTTT-3’; BOK Promoter3 Fw: 5’-
GCTCAGCCCAGATTTCAGTC-3’ and Rev: 5’-ACAAGGGTCACTGTGGAAGC-3’; BOK 
Promoter4 Fw: 5’-TGTTTATGTGATGCCCGAAG-3’ and Rev: 5’-
CCACCGATTCAGTTTCACCT-3’; BOK Mid Fw: 5’-CACCCAAGCATGTGTTTTTG-3’ and 
Rev: 5’-AGCCTGGGCAATAGAGTGAA-3’ and BOK End Fw: 5’-
GCATTCCCTTCATGCAATTT-3’ and Rev: 5’-GGGAAGAGGGAGACCGTTAG-3’. Fold 
enrichment was calculated using the 2
(-∆∆CT) 
method normalized to input and corrected for 
background using IgG controls. 
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Results 
BOK protein is downregulated in NSCLC tumors as well as in poorly differentiated and 
lymph node positive NSCLC tumors compared to matched lung parenchyma. BOK protein 
expression was significantly downregulated in NSCLC tumors as compared to the paired grossly 
normal adjacent lung parenchyma (P<0.001, n=102, Wilcoxon signed rank test). Regarding the 
histopathological tumor type, BOK protein expression was particularly downregulated in 
squamous cell lung carcinomas (SQCLC) (P=0.003, n=46, Wilcoxon signed rank test), but not in 
lung adenocarcinomas (P=0.368, n=43, Wilcoxon signed rank test) (Figure 1a). A representative 
image of BOK protein expression using near-infrared fluorophores for quantitative western blot 
analysis is shown in Figure 1d. Additionally, BOK protein was equally downregulated in tumors 
in men (P=0.012; n=67, Wilcoxon signed rank test) as well as in women (P=0.029; n=35, 
Wilcoxon signed rank test) (Figure 1a). Of note, BOK protein was downregulated in smokers 
(P<0.001; n=88, Wilcoxon signed rank test) but not in non-smokers (P=0.326; n=14, Wilcoxon 
signed rank test), as compared to the paired lung tissue (Figure 1a). Moreover, BOK protein was 
decreased in less differentiated tumors i.e. grades 2 (P=0.004, n=35, Wilcoxon signed rank test) 
and 3 (P=0.031, n=39, Wilcoxon signed rank test) as compared to the well differentiated 
matched lungs. 
We observed a decrease of BOK protein expression in stage III NSCLC as compared to the 
matched non-affected lungs (P=0.005; n=23; Wilcoxon signed rank test). Since staging is 
categorized according to the pTNM system (19), we analyzed whether BOK levels varied with 
tumor invasion to lymph nodes (pN). We found that in primary tumors with no spread to lymph 
nodes, there was no difference in BOK levels when compared to the control tissues (P=0.112, 
n=51, Wilcoxon signed rank test). However, lower BOK protein levels were detected in primary 
tumor cells spreading to nearby lymph nodes (pN1) (P=0.047, n=31, Wilcoxon signed rank test) 
and even less in tumors spreading to lymph nodes in mediastinum and/or around the carina 
(pN2) (P=0.021, n=18, Wilcoxon signed rank test) (Figure 1b). 
Next, we analyzed the relationship between BOK expression and a prognostic relevance for 
patient survival. Interestingly, BOK protein was weakly correlated with overall survival of 
lymph node positive NSCLC patients (P=0.0173, n=24; Spearman’s correlation) (Figure 1c).  
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BOK expression is predictive of survival in lymph node positive patients. Since BOK 
expression was weakly correlated with survival time in our patient group (Figure 1c), we asked 
whether BOK level was predictive of survival. Patients (n = 39) were stratified by BOK 
expression: less than the median or equal to or greater than the median.  When all patients were 
analyzed, the effect of BOK was not statistically significant (P = 0.62, Mantel test).  However, 
when analysis was limited to patients with lymph node involvement (n = 24, Figure 2), those 
with BOK expression equal to or above the median value had significantly longer survival (450 
[279, 621] days, mean [95% confidence intervals]) compared to those with BOK expression 
below the median (182 [124, 242] days, P = 0.002). The data suggest that BOK expression level 
is relevant to survival only in patients in whom the carcinoma has spread from the primary 
tumor. 
 
BOK expression is regulated by epigenetic mechanisms in NSCLC cells. We further 
investigated whether the variable levels of BOK mRNA detected in NSCLC cell lines (Figure 3) 
might be due to transcriptional silencing via epigenetic mechanisms. Using the software 
MethPrimer (23), we found an evolutionary conserved CpG island in the BOK promoter region 
extending into the second exon of the BOK gene (Figure 3a). As expected from in silico analysis, 
treatment with the DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine (decitabine) 
significantly increased BOK mRNA level in all 10 NSCLC cell lines studied (Figure 3b). Co-
treatment with trichostatin A further upregulated BOK mRNA in 6 out of 10 cell lines (Figure 
3b). By methylation specific PCR, we confirmed that methylation occurs directly in the BOK 
gene of NSCLC cells displaying low BOK levels (A549 and COLO-699), whereas no promoter 
methylation was detectable in the high BOK expressing H1299 cells (Figure 3c).  ChIP analysis 
confirmed that the histone cores of the nucleosomes surrounding the BOK gene are deacetylated 
in A549 cells, which can be reversed by the histone class I and II deacetylase inhibitor 
trichostatin A (Figure 3d). The combined treatment with decitabine did not further increase the 
H3K9 acetylation (Figure 3d and Supplemental data S5) implying that BOK promoter 
methylation and histone deacetylation are not dependent on one another. This was confirmed by 
ChIP analysis of DNA-dependent RNA polymerase II, which revealed that single treatments 
with either decitabine or trichostatin A are able to re-express the BOK gene. However, the 
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combined treatment had synergistic effects for the gene re-expression (Figure 3d), which 
correlated with mRNA levels (Figure 3b). BOK protein was markedly elevated in 5 of 10 studied 
cell lines upon decitabine treatment. In fact, BOK protein was upregulated more than 2 times in 
COLO-699, COR-L23, A549 and NCI-H520 cells (Figure 3e).  Trichostatin A increased BOK 
protein in the same cells except for COLO-699 (Figure 3e). 
The lack of correlation between BOK mRNA and protein levels may be partially explained by a 
previously reported high BOK protein turnover (1). However, as shown in Figure 4a, treatment 
of NSCLC cell lines with bortezomib, a specific 26S proteasome inhibitor, led to stabilization of 
BOK protein only in 2 out of 10 NSCLC cell lines (A549 and COLO-699). 
 
BOK overexpression does not induce significant apoptosis and does not sensitize towards 
drug-induced apoptosis in NSCLC cells. To investigate the role of BOK in NSCLC cell death, 
we used a 4-hydroxytamoxifen (4-OHT) inducible system to overexpress BOK in A549 cells (2). 
Despite readily detectable protein levels (Figure 4b) enforced BOK expression in A549 cells did 
not induce cell death, nor did it sensitize to cell death induced by cisplatin, etoposide, 
staurosporine (STS), fludarabine (FDB), TRAIL or 5-fluorouracil (5-FU) as assessed by flow 
cytometry using FITC-AnnexinV/PI staining (Figure 4c) and enzymatic caspase-3/-7 activity 
assay (data not shown). 
 
Loss of BOK negatively impacts on cellular proliferation rate in NSCLC cells. Interestingly, 
we noticed that BOK downregulation by RNA interference, as well as disruptive BOK gene 
editing using CRISPR/Cas9 (Figure 4b), decreased the proliferation rate of NSCLC cells, but not 
the number of dead cells as assessed by trypan blue exclusion (Figure 4d). Cells lacking BOK 
proliferated significantly slower, as confirmed by MTT assay (Supplemental data S2). Of note, 
besides prominent expression in the cytoplasm, we also detected significant amounts of BOK 
protein in purified nuclear fractions in 8 out of 10 cell lines (Figure 4e). Interestingly, upon 
downregulation of BOK, hardly any signal for the protein was detectable in the nuclear 
compartments (Figure 4f), which correlated with decreased proliferation. This was accompanied 
by a significant increase of p16
INK4A
 and p19
INK4D
 cell cycle inhibitors (Figure 4g). On the other 
hand, BOK overexpression did not influence the proliferation of A549 cells (Figure 4d and S2). 
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Interestingly, however, BOK overexpression in A549 cells inhibited 7-day anchorage 
independent growth in soft agar (Figure 4h).  
 
Role of BOK in epithelial-to-mesenchymal transition. To investigate a possible role of BOK 
in epithelial-to-mesenchymal transition (EMT), we treated cells with TGF-β2, an inducer of a 
mesenchymal cell type through the activation of SMAD2. We performed western blot and 
immunofluorescence analyses to verify the EMT marker expression. In A549 cells exposed to 10 
ng/ml of TGF-β2 for 48 hours, the mesenchymal marker vimentin was upregulated (Figure 5a 
and 5d). On the other hand, an epithelial marker, E-cadherin, was downregulated (Figure 5a and 
5d). However, A549 cells overexpressing BOK did not lose E-cadherin after TGF-β2 treatment 
(Figure 5a and 5d). Enforced expression of BOK in A549 cells treated with TGF-β2 did not only 
diminish expression of the full length 120 kDa E cadherin, but also of its 132 kDa precursor, 
suggesting not a proteolytic cleavage but rather regulation of its expression. These data indicate 
that BOK prevents the downregulation of E-cadherin. Moreover, morphological analysis 
revealed that BOK overexpression significantly abrogated TGF-β2-induced EMT (Figure 5b). 
Consistent with this interpretation, BOK inhibited TGF-β2-induced cell migration, as assessed 
by Boyden chamber migration assay (Figure 5c). Furthermore, we detected TGFβ2-induced 
increase of ATF4 as well as a shorter form of BOK that lacks the N-terminus due to alternative 
translation initiation at Met
15
 (13); ATF4, being required for cell invasion (24), was slightly 
diminished in TGFβ2-treated cell upon additional BOK overexpression and was accompanied by 
reduction of the shorter form of BOK (Figure 5e). 
 
Given the possible involvement of BOK in antagonizing EMT, we performed protein expression 
profiling by flow cytometry. We screened A549GEV16/BOK cells treated with or without TGF-
β and with or without 4-OHT for the expression of 238 surface proteins (supplemental data S3). 
Flow cytometry data were analyzed as previously described (25) with minor modifications. We 
used standardized percent of positive events and standardized mean fluorescence intensity of 
positive events for K-means clustering algorithm. Further, double weight was given to 
percentage of positive events. Flow cytometry data for the expression of proteins that changed 
with the treatments are shown in supplemental data S4. Specifically, TGF-β alone upregulated 
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EGFR and downregulated CD141, CD164, CD24, CD326 (EpCAM), CD38, Lymphotoxinβ 
receptor, MET, CD49f, CD54, CD70, CD71, CD321 (F11 Receptor) (Figure 6). 
However, enforced BOK expression abrogated TGFβ-induced upregulation of EGFR, and 
downregulation of MET and CD321. BOK alone upregulated MET and had a downmodulating 
effect on the expression of CD166, CD49f, Lymphotoxinβ Receptor, CD70, CD71 (TfR1) and 
CD94 (Figure 6). 
 
Discussion 
We and others have recently shown that BOK is widely expressed and detectable at the protein 
level in the mouse, with highest levels found in reproductive organs, brain and gastrointestinal 
tract, but also in the lung (1, 2, 9). On the other hand, BOK mRNA expression seems to be 
downregulated in many human cancer cell lines (26, 27, 28). Interestingly, Beroukhim and 
colleagues identified somatic copy number alterations (deletions) of the BOK gene locus in a 
wide screen of human primary cancers and cancer cell lines (16). These findings point toward a 
possible tumor suppressor function of BOK. In the present study, we found that BOK is not 
deleted at the genomic level in any of the 10 NSCLC cell lines studied. However, in BOK low-
expressing cell lines we identified an epigenetic silencing mechanism. Specifically, the DNA-
methyltransferase inhibitor decitabine upregulated BOK mRNA in all 10 cell lines tested up to 
13.8-fold (Figure 3b). Further, combination of decitabine with the histone deacetylase inhibitor 
trichostatin A had a synergistic effect on BOK mRNA induction in 6 out of 10 cells (Figure 3b). 
Our ChIP analysis revealed that the combined treatment of decitabine and trichostatin A has no 
synergistic effect on histone acetylation (Figure 3d and Supplemental data S5), implying that 
repression of the BOK gene occurs directly by methylation of CpG dinucleotides near the 
transcriptional start site of BOK (Figure 3b), thereby blocking the binding of transcription factors 
and not by recruitment of transcriptional repressors such as methyl-binding proteins that are 
associated with histone deacetylases. 
 Such epigenetic silencing might contribute to tumorigenesis as already shown for some BH3-
only proteins (29), and also to tumor metastasis. While BOK had no effect on acceleration of Eµ-
myc induced pre-B/B cell lymphoma, which is likely explained by the very low expression of 
BOK in lymphocytes (9), loss of BOK may slow NSCLC tumorigenesis as BOK downregulation 
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by RNA interference or CRISPR/Cas9 mediated gene editing resulted in significantly slower 
proliferation of NSCLC cells, correlating with loss of detection of nuclear BOK and increase of 
cell cycle inhibitors p16
INK4A
 and p19
INK4D
 (Figure 4d-g and S2). Given the prominent BOK 
localization in the nucleus (2,11) it is therefore attractive to speculate that the nuclear form BOK 
may interact with the cell cycle machinery, as proposed by Ray et al. in the context of 
trophoblast proliferation (12). Interestingly, the observed role of BOK in regulating proliferation 
opposes the cell cycle specific roles described for the anti-apoptotic BCL-2 family members 
BCL-2 and BCL-XL, which were shown to inhibit cell cycle progression to G1 by upregulation 
of p27 (30, 31).  
On the other hand, we show that BOK may have the potential to inhibit metastatic spread of 
developing NSCLC tumor cells by interfering with EMT (Figure 5). Unfortunately, the majority 
of NSCLC patients are diagnosed with advanced disease (17, 32). Patients with high-grade 
disease more often have a higher stage at diagnosis, a greater probability of recurrence or 
metastasis, and an overall shorter survival time after diagnosis (19). Although our patient 
population was heterogeneous, with patients ranging from Stage IA to IV, all were considered 
candidates for surgical resection. BOK expression level only appeared to impact survival in 
patients with lymph node involvement at the time of surgery. In this patient group, increased 
BOK protein expression was associated with significantly longer survival times (Figure 2). 
Importantly, we found that BOK levels were significantly decreased in tumors of lymph node 
positive patients and in less differentiated tumors compared to adjacent lung parenchyma (Figure 
1b). This phenotype might be favoured by epigenetic mechanisms during tumor progression 
(Figure 3, 33) and/or by proteasome-dependent regulation of BOK levels (1, 13). Importantly, 
we found a poor correlation between BOK mRNA and protein levels. However, our data indicate 
that mechanisms other than proteasomal turnover may be crucial to control BOK levels and 
activity in NSCLC cells (Figure 4a). 
The process by which cancer cells metastasize is thought to involve the transition of tumor cells 
with an epithelial phenotype to cells with mesenchymal traits. This process is accompanied with 
loss of tight junction proteins such as E-cadherin and upregulation of transcriptional repressors 
of tight junction proteins such as Twist, Snail or Slug. The resulting loss in polarity enables 
tumor cells to migrate and seed distant lesions. There is evidence concerning the involvement of 
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the tumor microenvironment in EMT (34, 35). It was previously shown, that certain cytokines 
such as IL-6, IL-8 or TGFβ initiate and/or sustain the mesenchymal cancer cell state (36, 37, 38). 
We used TGFβ to induce EMT in A549 cells, which express low levels of endogenous BOK. 
When exogenous BOK expression was induced in those cells, TGFβ–induced phenotypic change 
was prevented (Figure 5). Along the same line, enforced BOK expression significantly 
diminished anchorage-independent growth in soft agar (Figure 4h), and reduced TGFβ-induced 
transmigration (Figure 5c). Importantly, these effects are independent of BOK-induced cell 
death, as we showed that overexpression of BOK does not induce apoptosis in A549 cells 
(Figure 4d and S2). It is also worthwhile mentioning that A549 cells have acquired a dysfunction 
in the apoptosome machinery in the procaspase-9 activation probably by inhibitory 
phosphorylation of procaspase-9 (39). We and others have shown that BOK mainly localizes to 
the endoplasmic reticular membrane and BOK has accordingly been implicated with the 
regulation of ER stress, ERAD pathway and unfolded protein response (UPR) (1, 2, 6). Whereas 
we did not find BOK to affect the ATF6 or IRE1α arms of the UPR (not shown), our data show 
that BOK is likely involved in the modulation of the PERK>ATF4 arm in the context of TGFβ 
induced EMT, supporting studies that link PERK to EMT (24). Furthermore, the quantitative 
surface proteomics profiling showed upregulation of EGFR by TGFβ (Figure 6) suggesting the 
involvement of JUN N-terminal kinases pathway leading to JUN transcription factor activation 
(40) that binds to EGFR responsive element. Although enforced expression of BOK abrogated 
EGFR upregulation (Figure 6), which is indispensable for AKT activation leading to cell 
survival, BOK also abrogated TGFβ-mediated MET downregulation. Thus, BOK overexpression 
contributes to cell survival by inhibition of EGFR and upregulation of MET. However, sustained 
expression of MET and CD321 in TGFβ-treated BOK overexpressing cells shows epithelial state 
of the cells, thus confirming the BOK role in EMT inhibition. Moreover, overexpression of BOK 
downregulated membrane expression of CD166/ALCAM (Figure 6), which is implicated in 
NSCLC cancer cells migration and invasion in vitro (41) and its reduced expression inhibited 
skeletal metastasis in prostate cancer in vivo (42). 
In conclusion, we found that alteration of BOK expression in NSCLC tumors could account for 
differences in tumour invasion and thus overall survival of NSCLC patients. 
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Figure legends 
 
Figure 1 BOK protein expression in NSCLC tissues and adjacent lung tissue. (a and b) 
Expression data are shown as median with the upper ranges of 75% (box) and 90% (whisker) and 
the lower ranges of 25% (box) and 10% (whisker). Statistical differences were calculated by the 
Wilcoxon signed rank test. P values lower than 0.05 were considered statistically significant. (c) 
Spearman’s correlation between BOK protein expression in lymph node positive NSCLC and 
patients’ overall survival. (d) A representative image of quantitative western blot of total protein 
lysates from NSCLC and lung parenchyma. SQ - squamous cell lung carcinoma, LA - lung 
adenocarcinoma, UN- undifferentiated cell lung carcinoma, Lu - lung parenchyma.  
 
Figure 2. BOK expression level is predictive of survival in lymph node positive patients. 
Kaplan-Meier survival analysis: dashed lines = 95% confidence intervals. P-value was calculated 
according to the Mantel test. Grey < median BOK, Black ≥ median BOK. 
 
Figure 3 The BOK gene is epigenetically silenced in NSCLC cell lines. (a) Bioinformatic 
analysis of human BOK gene methylation. CpG island prediction was based on DNA regions > 
100bp with a CG content > 0.5 and observed/expected CpG ratio above 0.6. An input sequence 
of 1600-base long DNA around the BOK transcriptional start (arrow) was searched. (b) Cells 
were treated as indicated with 10 µM of decitabine for 72h or 300 nM of trichostatin A for 24 h 
or a combination of both; mRNA expression was measured by RT-qPCR. Data represent mean ± 
S.E.M from 3 experiments. Fold change between control and treatment is indicated above the 
bar. (c) Methylation status of BOK promoter by methylation specific PCR in A549, COLO-699 
and H1299 cells using primers for methylated (M) or unmethylated (U) bisulfite-modified DNA. 
Representative example from 3 independent experiments is shown. (d) Acetylated H3K9 active 
chromatin mark and RNA polymerase II binding throughout the BOK gene in A549 cells. A549 
cells treated with decitabine (72h) and/or trichostatin A (24h) were analyzed by ChIP with anti-
H3K9Ac, anti-Pol II and IgG, followed by qPCR analysis of amplicons in the promoter and in 
the body of the BOK gene (internal control). Error bars indicate the standard error of the mean 
(SEM) of two biological replicates. (e) NSCLC cells were treated as indicated in (b) and total 
Page 21 of 29
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
Moravcikova et al. Bcl-2 family member BOK in non-small cell lung carcinoma 
22 
 
protein lysates analyzed by western blotting.  
 
Figure 4 Stabilization of BOK protein by bortezomib, cell death and proliferation analyses. (a) 
Cells were treated with bortezomib at the indicated concentration for 24 h; total protein lysates 
were analyzed by western blotting. (b) Western blot analysis of total protein lysates from 
A549GEV16/BOK and A549GEV16only cells treated with or without 100 nM 4-OHT for 48h 
and of H1299, A549 and LXF-289 cells with downregulated BOK using shRNA or 
CRISPR/Cas9 technology. (c) A549GEV16/BOK or A549GEV16only cells were pretreated with 
or without 100nM 4-OHT overnight and treated with cisplatin, 5-FU, etoposide, staurosporine, 
fludarabine or TRAIL for 48 h. Viability was assessed by FITC-AnnexinV/PI staining using flow 
cytometry. Data represent mean ± S.E.M. from 3-6 independent experiments. (d) Trypan-blue 
exclusion assay of cell proliferation. Data represent mean ± S.E.M. from 3 independent 
experiments. Statistical analysis was performed using Student’s t-test. Asterisks indicate a P 
value lower than 0.05. (e and f) Detection of nuclear BOK by western blot analysis. Nuclear and 
cytoplasmic fractions were prepared from NSCLC cells. The purity of fractions was confirmed 
by detection of PARP (nuclear) or Tubulin (cytoplasmic). The cytoplasmic/nuclear ratio of BOK 
protein expression (C/N) is shown below the blots. (g) mRNA expression of GAPDH-
normalized cell cycle regulators by RT-qPCR. Data represent mean ± S.E.M. from 3 independent 
experiments.  Asterisks indicate a P value lower than 0.05 analyzed by Student’s t-test. (h) 
Anchorage-independent growth of A549GEV16/BOK cells in soft agar for 7 days. Cells were 
treated as indicated with or without 100 nM 4-OHT.  
 
Figure 5 BOK inhibits EMT. Cells were pretreated with or without 100 nM 4-OHT and treated 
with or without 10 ng/ml of TGFβ2 for 48 hours. (a) Whole cell lysates were analyzed by 
western blotting using anti-E-cadherin, anti-actin (loading control), anti-BOK (same membrane), 
anti-vimentin and anti-GAPDH (loading control) antibodies. (b) Histogram of morphological 
changes of A549GEV16/BOK cells: the length and width of at least 100 cells were measured per 
condition. (c) Boyden chamber migration assay (d) Confocal scanning micrographs of 
A549GEV16/BOK cells. Anti-vimentin (green) and anti-E-cadherin (red) antibodies were used. 
All cells were counterstained with DAPI (blue). The same exposure times and LUT settings were 
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used. (e) Western blot analysis of A549GEV16/BOK whole cell lysates treated as indicated 
above for 12, 24 and 48 hours. Membrane was probed with anti-ATF4, anti-BOK and anti-
GAPDH (loading control) antibodies. One representative immunoblot is shown from three 
independent experiments. 
 
Figure 6 Cell surface protein expression by flow cytometry. Thirty-eight markers shown were 
selected from 238 measured specificities on the basis of strength of expression or extent of 
modulation. Cells were treated as indicated with or without 100 nM 4-OHT overnight, following 
addition of 10 ng/ml of TGFβ or vehicle and incubated for 48 h. K-means cluster 0: no 
expression, 1: low expression, 2: moderate expression, 3: high expression. Y axis: Cell surface 
marker expression in untreated A549GEV16/BOK. Color coded boxes indicate changes between 
treatments (4-OHT and/or TGFβ) and control cells (vehicle-treated). Dashed lines indicate 
markers that were modulated by BOK overexpression. 
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